{"success":true,"data":{"pressRelease":{"id":"163726","rtpr_id":"nBw1w0Kw8a-20261008","ticker":"AVBP","exchange":"NASDAQ","all_tickers":["AVBP"],"title":"AVBP Investors with $100,000 in Losses Have Opportunity to Join ArriVent BioPharma, Inc. Fraud Investigation with SBS Law","author":"Business Wire","published_at":"2026-10-08T02:56:00.091Z","article_body":"AVBP Investors with $100,000 in Losses Have Opportunity to Join ArriVent\nBioPharma, Inc. Fraud Investigation with SBS Law\n\nSchall, Brown & Schwartz\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fschallfirm.com%2F&esheet=54618269&newsitemid=20261007099221&lan=en-US&anchor=Schall%2C+Brown+%26amp%3B+Schwartz&index=1&md5=07cbd47187056974ada2f0992b7fe0f3)\nLLP (“SBS”), a national shareholder rights litigation firm, announces that\nit is investigating claims on behalf of investors of ArriVent BioPharma, Inc.\n(“ArriVent” or “the Company”) (NASDAQ: AVBP\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Ffinance.yahoo.com%2Fquote%2FAVBP&esheet=54618269&newsitemid=20261007099221&lan=en-US&anchor=AVBP&index=2&md5=7428235d1237b1c34a7737bac7b1e4dc)\n) for violations of the securities laws.\n\nINVESTIGATION DETAILS: The investigation focuses on whether the Company issued\nfalse and/or misleading statements and/or failed to disclose information\npertinent to investors. ArriVent revealed on October 6, 2026, that its global\nPhase 3 FURVENT trial of firmonertinib failed to achieve statistically\nsignificant results for its primary endpoint. Based on this news, shares of\nArriVent fell sharply on the same day.\n\nIf you are a shareholder who suffered a loss, click here to participate\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fschallfirm.com%2Fcases%2Farrivent-biopharma-inc%2F&esheet=54618269&newsitemid=20261007099221&lan=en-US&anchor=click+here+to+participate&index=3&md5=ec4a11b58dd04036d2a12ecd2172b8b9)\n.\n\nWe also encourage you to contact Brian Schall or David Schwartz of Schall,\nBrown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA\n90067, at 310-301-3335, to discuss your rights free of charge. You can also\nreach us through the firm's website at www.schallfirm.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fpr.report%2FmIwBkOrU&esheet=54618269&newsitemid=20261007099221&lan=en-US&anchor=www.schallfirm.com&index=4&md5=d12bb2a8b5e7c26a6434b3fc650d3b78)\n, or by email at david@schallfirm.com (mailto:david@schallfirm.com) .\n\nWHY SBS? Schall, Brown & Schwartz LLP represents investors around the\nworld and specializes in securities class action lawsuits and shareholder\nrights litigation. Bringing together the extensive experience and diverse\nskillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz,\nSBS is dedicated to aggressively advocating for every investor.\n\nThis press release may be considered Attorney Advertising in some\njurisdictions under the applicable law and rules of ethics.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20261007099221/en/\n(https://www.businesswire.com/news/home/20261007099221/en/)\n\nSchall, Brown & Schwartz LLP\n\nBrian Schall, Esq.,\n\nAndrew Brown, Esq.,\n\nDavid Schwartz, Esq.,\n\nwww.schallfirm.com \n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.schallfirm.com&esheet=54618269&newsitemid=20261007099221&lan=en-US&anchor=www.schallfirm.com&index=5&md5=f826f4184188f5df3dadae56c1f4b8c2)\n\nOffice: 310-301-3335\n\ninfo@schallfirm.com (mailto:info@schallfirm.com)\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw1w0Kw8a-20261008","title":"AVBP Investors with $100,000 in Losses Have Opportunity to Join ArriVent BioPharma, Inc. Fraud Investigation with SBS Law","author":"Business Wire","ticker":"AVBP","created":"2026-10-08T02:56:00.091Z","tickers":["AVBP"],"exchange":"NASDAQ","article_body":"AVBP Investors with $100,000 in Losses Have Opportunity to Join ArriVent\nBioPharma, Inc. Fraud Investigation with SBS Law\n\nSchall, Brown & Schwartz\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fschallfirm.com%2F&esheet=54618269&newsitemid=20261007099221&lan=en-US&anchor=Schall%2C+Brown+%26amp%3B+Schwartz&index=1&md5=07cbd47187056974ada2f0992b7fe0f3)\nLLP (“SBS”), a national shareholder rights litigation firm, announces that\nit is investigating claims on behalf of investors of ArriVent BioPharma, Inc.\n(“ArriVent” or “the Company”) (NASDAQ: AVBP\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Ffinance.yahoo.com%2Fquote%2FAVBP&esheet=54618269&newsitemid=20261007099221&lan=en-US&anchor=AVBP&index=2&md5=7428235d1237b1c34a7737bac7b1e4dc)\n) for violations of the securities laws.\n\nINVESTIGATION DETAILS: The investigation focuses on whether the Company issued\nfalse and/or misleading statements and/or failed to disclose information\npertinent to investors. ArriVent revealed on October 6, 2026, that its global\nPhase 3 FURVENT trial of firmonertinib failed to achieve statistically\nsignificant results for its primary endpoint. Based on this news, shares of\nArriVent fell sharply on the same day.\n\nIf you are a shareholder who suffered a loss, click here to participate\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fschallfirm.com%2Fcases%2Farrivent-biopharma-inc%2F&esheet=54618269&newsitemid=20261007099221&lan=en-US&anchor=click+here+to+participate&index=3&md5=ec4a11b58dd04036d2a12ecd2172b8b9)\n.\n\nWe also encourage you to contact Brian Schall or David Schwartz of Schall,\nBrown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA\n90067, at 310-301-3335, to discuss your rights free of charge. You can also\nreach us through the firm's website at www.schallfirm.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fpr.report%2FmIwBkOrU&esheet=54618269&newsitemid=20261007099221&lan=en-US&anchor=www.schallfirm.com&index=4&md5=d12bb2a8b5e7c26a6434b3fc650d3b78)\n, or by email at david@schallfirm.com (mailto:david@schallfirm.com) .\n\nWHY SBS? Schall, Brown & Schwartz LLP represents investors around the\nworld and specializes in securities class action lawsuits and shareholder\nrights litigation. Bringing together the extensive experience and diverse\nskillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz,\nSBS is dedicated to aggressively advocating for every investor.\n\nThis press release may be considered Attorney Advertising in some\njurisdictions under the applicable law and rules of ethics.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20261007099221/en/\n(https://www.businesswire.com/news/home/20261007099221/en/)\n\nSchall, Brown & Schwartz LLP\n\nBrian Schall, Esq.,\n\nAndrew Brown, Esq.,\n\nDavid Schwartz, Esq.,\n\nwww.schallfirm.com \n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.schallfirm.com&esheet=54618269&newsitemid=20261007099221&lan=en-US&anchor=www.schallfirm.com&index=5&md5=f826f4184188f5df3dadae56c1f4b8c2)\n\nOffice: 310-301-3335\n\ninfo@schallfirm.com (mailto:info@schallfirm.com)\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-10-08T02:56:00.127333496Z","server_sent_at_ms":1791428160127},"received_at":"2026-10-08T02:56:00.177Z","source_url":"https://www.businesswire.com/news/home/20261007099221/en/"},"analysis":{"id":"152173","press_release_id":"163726","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":["Phase 3 FURVENT trial of firmonertinib failed primary endpoint; shares fell sharply","securities-fraud investigation signals potential litigation overhang"],"eventType":"legal_litigation","narrative":"Schall, Brown & Schwartz LLP announced it is investigating ArriVent BioPharma (NASDAQ: AVBP) for potential securities-law violations, soliciting investors with losses over $100,000.\n\nThe investigation follows the company's October 6 disclosure that its Phase 3 FURVENT trial of firmonertinib missed statistical significance on its primary endpoint, sending shares sharply lower.\n\nThis release is plaintiff-firm marketing rather than an issuer disclosure; the material news remains the trial failure previously announced.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation following prior trial failure -- suppress; the material event was the October 6 Phase 3 miss."},"keyFigures":{"drugName":"firmonertinib","phaseOfTrial":"Phase 3"},"quotedText":"ArriVent revealed on October 6, 2026, that its global Phase 3 FURVENT trial of firmonertinib failed to achieve statistically significant results for its primary endpoint.","namedEntities":{"people":[{"name":"Brian Schall","role":"founding partner, Schall, Brown & Schwartz LLP"},{"name":"David Schwartz","role":"founding partner, Schall, Brown & Schwartz LLP"}],"products":["firmonertinib"],"companies":[{"name":"ArriVent BioPharma, Inc.","ticker":"AVBP","relationship":"subject of investigation"},{"name":"Schall, Brown & Schwartz LLP","relationship":"plaintiff law firm"}],"dollarAmounts":[{"amount":"$100,000","context":"shareholder loss threshold to join investigation"}]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm solicitation by Schall, Brown & Schwartz following an already-disclosed Phase 3 trial failure. No certified class or settlement; the underlying negative news (FURVENT miss) occurred October 6 and is not new."},"tickerRelevance":{"others":[],"primary":"AVBP"},"globalImportance":15,"audienceRelevance":12,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap biotech","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Schall, Brown & Schwartz LLP announced it is investigating ArriVent BioPharma (NASDAQ: AVBP) for potential securities-law violations, soliciting investors with losses over $100,000.\n\nThe investigation follows the company's October 6 disclosure that its Phase 3 FURVENT trial of firmonertinib missed statistical significance on its primary endpoint, sending shares sharply lower.\n\nThis release is plaintiff-firm marketing rather than an issuer disclosure; the material news remains the trial failure previously announced.","key_figures":{"drugName":"firmonertinib","phaseOfTrial":"Phase 3"},"named_entities":{"people":[{"name":"Brian Schall","role":"founding partner, Schall, Brown & Schwartz LLP"},{"name":"David Schwartz","role":"founding partner, Schall, Brown & Schwartz LLP"}],"products":["firmonertinib"],"companies":[{"name":"ArriVent BioPharma, Inc.","ticker":"AVBP","relationship":"subject of investigation"},{"name":"Schall, Brown & Schwartz LLP","relationship":"plaintiff law firm"}],"dollarAmounts":[{"amount":"$100,000","context":"shareholder loss threshold to join investigation"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-08T02:56:07.354Z","global_importance":15,"audience_relevance":12,"importance_components":{"tickerTier":"small-cap biotech","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"durationMs":7166,"modelName":"glm-5.3-flashx"}}